Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL828379 | 0.91 | MAPK14 (0.78) | MAPK14MAPK10 | |
| SCHEMBL828130 | 0.88 | MAPK14 (0.60) | MAPK14 | |
| SCHEMBL828307 | 0.86 | MAPK14 (0.80) | MAPK14 | |
| SCHEMBL828252 | 0.85 | MAPK14 (0.55) | MAPK14MAPK10 | |
| SCHEMBL828733 | 0.85 | MAPK14 (0.58) | MAPK14 | |
| SCHEMBL828605 | 0.82 | MAPK14 (0.53) | MAPK14 | |
| SCHEMBL828544 | 0.78 | MAPK14 (0.55) | MAPK14 | |
| SCHEMBL4466663 | 0.77 | MAPK14 (0.61) | MAPK14 | |
| SCHEMBL4471619 | 0.76 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL828375 | 0.76 | MAPK14 (0.63) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170313661-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2017-11-02 | — | — | US | disclosed |
| US-20170313661-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2017-11-02 | — | — | US | disclosed |
| US-9617221-B2 | Kinase modulators for the treatment of cancer | SYNOVO GMBH (DE) | 2017-04-11 | — | — | US | disclosed |
| US-9617221-B2 | Kinase modulators for the treatment of cancer | SYNOVO GMBH (DE) | 2017-04-11 | — | — | US | disclosed |
| US-9617221-B2 | Kinase modulators for the treatment of cancer | SYNOVO GMBH (DE) | 2017-04-11 | — | — | US | disclosed |
| US-20130045938-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2013-02-21 | — | — | US | disclosed |
| US-20130045938-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2013-02-21 | — | — | US | disclosed |
| US-20130045938-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2013-02-21 | — | — | US | disclosed |
| US-8143294-B2 | 2-sulfanyl-substituted imidazole derivatives and their use as cytokine inhibitors | BURNET MICHAEL (DE) | 2012-03-27 | — | — | US | disclosed |
| US-8143294-B2 | 2-sulfanyl-substituted imidazole derivatives and their use as cytokine inhibitors | BURNET MICHAEL (DE) | 2012-03-27 | — | — | US | disclosed |
| US-8143294-B2 | 2-sulfanyl-substituted imidazole derivatives and their use as cytokine inhibitors | BURNET MICHAEL (DE) | 2012-03-27 | — | — | US | disclosed |
| WO-2011100769-A2 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | SYNOVO GMBH (DE) | 2011-08-18 | — | — | WO | disclosed |
| US-20090270462-A1 | 2-SULFANYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SYNOVO GMBH (DE) | 2009-10-29 | — | — | US | disclosed |
| US-20090270462-A1 | 2-SULFANYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SYNOVO GMBH (DE) | 2009-10-29 | — | — | US | disclosed |
| US-20090270462-A1 | 2-SULFANYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SYNOVO GMBH (DE) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313661-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | MAP3K10, MAP3K12, MAP3K20 | MAPK14 53/4885MAPK10 23/4885 |
| US-20130045938-A1 | KINASE MODULATORS FOR THE TREATMENT OF CANCER | MAP3K10, MAP3K12, MAP3K20 | MAPK14 53/4885MAPK10 23/4885 |
| US-20090270462-A1 | 2-SULFANYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | IL2, IL2RA, IL1B | MAPK14 699/4885MAPK10 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.